BioSante 8K for 2nd quarter results

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
__________________

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
__________________
 
Date of Report (Date of earliest event reported):
August 12, 2005
 

BIOSANTE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware
1-31812
58-2301143
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)

 
111 Barclay Boulevard
Lincolnshire, Illinois
 
60069
(Address of principal executive offices)
(Zip Code)

(847) 478-0500
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 



Section 2 — Financial Information

Item 2.02      Results of Operations and Financial Condition

    On August 12, 2005, BioSante Pharmaceuticals, Inc. publicly announced its financial results for the second quarter ended June 30, 2005.  For further information, please refer to the press release attached hereto as Exhibit 99.1, which is incorporated by reference herein.
 
    The information contained in this report and the exhibit hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filings made by BioSante Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.
 
Section 9 — Financial Statements and Exhibits

Item 9.01    Financial Statements and Exhibits

(c)   Exhibits.

Exhibit No.
Description
99.1
Press release issued August 12, 2005.






SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
BIOSANTE PHARMACEUTICALS, INC.
     
   
 
 		  
 		  
 
Date: August 12, 2005 By:   /s/ Phillip B. Donenberg
 
  Chief Financial Officer, Treasurer, and Secretary

 


BIOSANTE PHARMACEUTICALS, INC.
FORM 8-K
EXHIBIT INDEX
 

Exhibit No.            Description                                                             Method of Filing              

99.1          Press Release issued August 12, 2005                 Filed herewith